Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab in Resected Stage IIB/IIC Melanoma
NCT03405155Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2018
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in cutaneous melanoma (CM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03405155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405155.